<DOC>
	<DOCNO>NCT00045305</DOCNO>
	<brief_summary>RATIONALE : Photopheresis treat patient 's blood drug ultraviolet light outside body kill white blood cell . Giving photopheresis , pentostatin , radiation therapy donor bone marrow stem cell transplant help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving pentostatin transplant cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give pentostatin together photopheresis total-body irradiation work donor bone marrow transplant treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Reduced-Intensity Regimen Before Donor Bone Marrow Transplant Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate patient myelodysplastic syndrome treat reduced-intensity allogeneic bone marrow transplantation , include photopheresis , total body irradiation , pentostatin . - Determine disease-free overall survival patient treat regimen . - Determine engraftment rate donor cell patient treat regimen . - Determine extent duration acute chronic graft-versus-host disease patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This single-arm , two-stage , multicenter phase II study . - Preparative Regimen : Patients undergo photopheresis use methoxsalen day -7 -6 receive pentostatin intravenously ( IV ) continuously day -5 -4 . Total body irradiation administer day -3 -2 total 3 dos . - Transplantation : Allogeneic bone marrow peripheral blood stem cell infuse day 0 . - Acute graft-vs-host-disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV day -1 30 orally every 12 hour . Cyclosporine dose taper begin day 50 continue 6 month absence GVHD . Once cyclosporine dose significantly decrease , oral mycophenolate mofetil ( MMF ) administer twice day . MMF dose tapered 12 month absence GVHD . Patients also receive methotrexate IV day 1 3 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 33 patient would accrue study within 2.1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>One follow cytologically prove myelodysplastic syndrome Refractory anemia ( RA ) RA ring sideroblast RA excess blast Chronic myelomonocytic leukemia International Prognosis Scoring System ( IPSS ) score least 0.5 OR red cell transfusion dependence least 6 month ( 2 unit per month ) Patients IPSS score less 0.5 may eligible provide previously high IPSS score receive chemotherapy time Suitable human leukocyte antigen ( HLA ) match donor ( relate unrelated ) available No cord blood donor Related donor must genotypically match ( HLA A , B DR ) 5/6 6/6 locus may sibling , parent , child Unrelated donor must high resolution type do A , B , C DR , must match may single antigen allele mismatch one locus Patients must &lt; 20 % blast bone marrow study within 1 month study entry Age 18 70 year Eastern Cooperative Oncology Group performance status 01 Life expectancy least 6 month At least 90 day since prior autologous bone marrow transplantation Serum erythropoietin level great 100 patient receive prior course epoetin alfa No iron deficiency Iron deficiency anemia treat iron replacement therapy allow Bilirubin le 2.0 mg/dL Alkaline phosphatase less 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 3 time ULN Creatinine le 2.0 mg/dL OR creatinine clearance great 50 mL/min Left ventricular ejection fraction ( LVEF ) least 45 % Multigated Acquisition scan ( MUGA ) echocardiogram Carbon Monoxide Diffusing Capacity ( DLCO ) least 50 % predict ( correct hemoglobin ) Forced expiratory volume 1 second ( FEV_1 ) least 50 % predict Recovered prior chemotherapy Physically psychologically capable undergo study regimen Able receive 600 cGy total body irradiation HIV negative Negative pregnancy test Pregnant nursing Having medical condition would reduce life expectancy Active ongoing infection Prior myeloablative nonmyeloablative allogeneic transplantation Myelodysplastic syndrome acute myeloid leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>